Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in BioMarin Pharmaceutical Inc., Halozyme Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Latest Biotechnology and BioMarin Pharmaceutical Inc., Halozyme Therapeutics, Inc. Stock News
As of November 6, 2025, BioMarin Pharmaceutical Inc. had a $10.0 billion market capitalization, compared to the Biotechnology median of $203.9 million. BioMarin Pharmaceutical Inc.’s stock is down 21.7% in 2025, down 3.9% in the previous five trading days and down 21.47% in the past year.
Currently, BioMarin Pharmaceutical Inc.’s price-earnings ratio is 19.3. BioMarin Pharmaceutical Inc.’s trailing 12-month revenue is $3.1 billion with a 16.8% net profit margin. Year-over-year quarterly sales growth most recently was 4.1%. Analysts expect adjusted earnings to reach $3.573 per share for the current fiscal year. BioMarin Pharmaceutical Inc. does not currently pay a dividend.
As of November 6, 2025, Halozyme Therapeutics, Inc. had a $8.0 billion market cap, putting it in the 76th percentile of all stocks. Halozyme Therapeutics, Inc.’s stock is up 42.7% in 2025, up 4.7% in the previous five trading days and up 16.97% in the past year.
Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 14.4. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.2 billion with a 47.9% net profit margin. Year-over-year quarterly sales growth most recently was 22.1%. Analysts expect adjusted earnings to reach $6.120 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.
How We Compare BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions